A targeted medicine can now be used earlier in the treatment of a small but important group of people with advanced lung cancer following a new US Food and Drug Administration decision.
The FDA has granted accelerated approval for sevabertinib for adults with locally advanced or metastatic non-squamous non-small-cell lung cancer whose tumors carry particular activating HER2, also called ERBB2, mutations.
The important change is not that sevabertinib is an entirely new drug.
It had previously been approved for some patients who had already received systemic treatment.
The new decision allows eligible patients to receive it before previous systemic therapy for advanced disease.
Why do genetic mutations matter in lung cancer?
Lung cancer is no longer treated as one single disease.
Two people can have cancers that look similar under a microscope but contain different genetic changes that drive the cancer cells to grow.
Modern molecular testing can identify some of these changes.
When researchers have a drug capable of blocking the abnormal molecular signal, treatment can sometimes be selected according to the tumor's mutation rather than using the same approach for every patient.
What is HER2?
HER2 is a protein involved in signals controlling cell growth.
The gene carrying the instructions for this protein is also known as ERBB2.
Certain mutations can leave this growth signal abnormally active and contribute to cancer development.
HER2 is widely known because of its role in some breast cancers, but HER2 abnormalities can also occur in other cancers, including a small proportion of non-small-cell lung cancers.
Sevabertinib is designed to inhibit abnormal HER2 signalling.
What evidence led to the new approval?
The FDA decision was supported by results from the ongoing SOHO-01 study.
Among 69 previously untreated patients included in the relevant group, approximately 75% experienced substantial tumor shrinkage.
Among those whose tumors responded, 73% maintained that response for at least six months, while 38% maintained it for at least 12 months.
These results are encouraging for a molecularly selected group of patients with advanced lung cancer.
Does 75% mean that 75% of patients survived?
No.
The 75% figure refers to the proportion of patients whose tumors showed a defined response to treatment.
It is not a survival rate.
Whether the treatment ultimately allows patients to live longer, or provides better overall outcomes than the best alternative first treatment, requires additional evidence.
Why is this an accelerated approval?
The FDA's accelerated-approval pathway allows earlier authorization of treatments for serious diseases when evidence shows a result that is reasonably likely to predict meaningful clinical benefit.
In this case, the approval is based largely on how many tumors responded and how long those responses lasted.
The relevant evidence came from a relatively small group of patients and did not come from a randomized comparison against standard first-line treatment.
That is why confirmatory research remains important.
An ongoing randomized study, SOHO-02, is intended to verify the clinical benefit.
Are there important side effects?
Yes.
Like other powerful targeted cancer medicines, sevabertinib can cause significant adverse effects.
Important risks identified in the prescribing information include severe diarrhea, liver toxicity, inflammation of the lungs known as pneumonitis, reduced heart function and eye-related toxicity.
Treatment therefore requires specialist oncology assessment and monitoring.
Who does this approval apply to?
It does not apply to everyone with lung cancer.
The approval applies to a molecularly defined group of adults with locally advanced or metastatic non-squamous non-small-cell lung cancer whose tumors contain qualifying activating HER2 mutations.
That makes appropriate tumor testing essential.
Why does this matter?
This approval demonstrates how cancer treatment is increasingly being divided according to the molecular characteristics of each person's tumor.
For some patients, identifying a specific mutation can now directly determine which treatment can be offered from the beginning of advanced-disease therapy.
However, the accelerated approval still requires confirmation that the impressive tumor responses translate into meaningful longer-term clinical benefit.
Evidence so far
FDA accelerated approval based on strong tumor-response results — confirmatory randomized evidence is still required
The early response data are encouraging, but the relevant patient group was small and the study was not a randomized first-line comparison.
The ongoing confirmatory trial will be important in determining the treatment's longer-term place in lung-cancer care.
